Platform user capacity will be increased within the weeks following the launch.

Users can sign up for early access from today and are asked to answer a short set of questions that amongst others evaluate their intended use of the platform. Users will be prioritized based on suitability and selected based on criteria they meet.

Please cite our technical report available at latent-x.latentlabs.com.

We intend to bring more capabilities to the Latent Labs Platform, including expanded therapeutic modalities such as nanobodies and antibodies.

The Latent Labs Platform features the in silico metrics that were used to rank and select successfully lab-validated binders. A ‘Pass’ score is assigned to designs that are passing those metrics. Designs close to passing may also be valid binders.

The generation of binders can happen within seconds, while scoring using structure prediction models takes a little longer. Times are dependent on batch sizes and accelerator availability on our platform.

The Latent Labs platform gives access to our first frontier model, Latent-X, and allows scientists to replicate the AI workflows that were used in generating lab-validated binders as detailed in our accompanying tech report. Key differentiating features include lab-validated binder hits on every tested target, stronger binding affinities than prior methods, lab validated target specificity, and joint protein sequence and structure generation.

Typical use cases are the design of protein target specific protein binders, such as macrocycles (also known as cyclic peptides) and mini-binders for research or therapeutic applications. The platform launches with macrocycles and mini-binders, with more features to come.

Contact partnerships@latentlabs.com

Commercial usage of the beta version of the Latent Labs Platform is expressly permitted within the bounds of the license agreement. All users are permitted to keep and use the protein sequences they generate via a non-exclusive license.